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1. Introduction

Phase II studies in oncology have evolved over the previous several decades. Currently, the
number of drugs in phase II development has increased, and patient eligibility has narrowed due
to targeted agents, competing trials and curative therapies in the first-line setting. As a result of
these changes, more attention needs to be focused toward conducting more efficient phase II
trials. Given the increased difficulty in accruing patients to phase II studies and the ethical
concern of treating patients with agents that are ineffective, there is significant motivation to stop
a single arm trial early when the investigational agent shows evidence of a low response rate.

Many single arm phase II trials in oncology continue to be developed using tumor response, or
another binary measure of clinical efficacy, as the primary outcome. Unlike comparative trials,
which are often designed to stop early if there is convincing evidence that one treatment
regimen is superior to the other, single arm studies usually only stop for futility. The most
popular phase II design in oncology clinical trials has been the Simon two-stage design [1]
which allows one early look to stop for futility and maintains overall type I and type II errors while
increasing the sample size only modestly when compared to a single stage design. This design
is easy to perform in practice and is simple to design using commonly available software and
web-based programs. For any given set of study parameters (null and alternative response
rates and type I and type II errors), there are many designs that can be performed with one
early look. Simon defined several criteria for choosing the best design. The “optimal” design has
the smallest expected sample size under the null hypothesis, while the “minimax” design has
the smallest sample size at the end of the second stage of the trial [1].

The Simon two-stage design only allows stopping at one point during the trial. Using other
design approaches, it is possible to consider multiple stopping times, which provide higher
chances of stopping the trial if the treatment is ineffective. A related extension of the Simon twostage design is the three-stage design [2]. Both the two- and three-stage designs mentioned
thus far are frequentist in nature and measure evidence for early stopping and for rejecting
hypotheses using p-values. In addition to the two- and three-stage designs mentioned, there are
others proposed, mostly varying in their optimization criteria [3-6]. Due to the very nature of pvalues and the problems with accumulating type I errors by repeated hypothesis testing in the
frequentist setting, a number of other early stopping criteria for single arm phase II studies with
binary endpoints have been proposed.

We propose a likelihood-based stopping design that follows the evidential paradigm and relies
on the likelihood principle [7]. The observed data is evaluated under the null and alternative
hypotheses and the resulting likelihood ratio is used for making inferences. This approach does
not rely on prior information and the evidence can be quantified in a relatively simple way.
Unlike frequentist designs in which type I error rates at successive interim looks can accumulate
to unacceptable levels, the evidential paradigm relies on the universal bound, which limits the
probability of misleading evidence in favor of the incorrect hypothesis. As a result, likelihoodbased designs can look at the data early and often and terminate a trial if there is sufficiently
strong evidence, and the probability of making an incorrect conclusion can be relatively small.
Blume clarified some potential misconceptions about the evidential paradigm [8]. It is true that
more frequent looks at the data will lead to higher chances of selecting an incorrect hypothesis
in the evidential paradigm: we do not contend that our approach will lead to the same error rates
as looking at the data only once or twice. The probability of misleading evidence is bounded
regardless of the number of interim looks and the bound can be controlled.

There is a large literature selection on the design of single arm phase II trials [9-11]. Even so, in
cancer research, the Simon two-stage design is the most commonly adopted when clinical
response is the outcome of interest. Lee and Liu proposed a predictive probability design,
described in more detail in section 3.2 [12] and similar to an earlier version by Herson [13]. They
convincingly argue that multi-stage frequentist designs can be challenging to implement and
analyze. Frequentist inferences condition on the study design, so that if an early look is
implemented earlier or later than originally planned, the stopping rules and statistical properties
are then undefined and inference becomes challenging. Other authors have described this in
more detail and proposed some design and inference solutions [14, 15]. Bayesian and likelihood
approaches do not suffer from this complication; both approaches rely on the likelihood principle
which uses all data collected and does not depend on the design from which the data arose. A
number of other Bayesian approaches exist in this setting but have not been widely adopted
[16-24]. There are several reasons that might explain this. First, the inclusion of a prior
distribution may be unacceptable to some. Second, Bayesian designs are often assumed to be
more computationally challenging. For some Bayesian approaches, these assertions are not
well-founded because priors can be selected that have little influence on the inferences (i.e.,
weak priors), and calculations for early stopping can often be done prior to the implementation
of the trial. But arguably the most challenging problem to overcome by using a non-frequentist
design approach is describing the resulting evidence. Medical researchers have become
accustomed to the interpretation of p-values such that other forms of evidence become hard to
interpret. A similar phenomenon exists with power calculations. Non-frequentist design
proponents have been required to translate their design properties into type I and II errors so
that the research community can interpret findings in the frequentist paradigm. The likelihood
approach allows for this type of conversion due to the universal bound and by quantifying the
probability of misleading and weak evidence as will be described in the following sections.

2. Methods
2.1. The likelihood approach

Historically, the dominating design approach has been frequentist, based on theories developed
by Neyman & Pearson and by R.A. Fisher, and we refer to this approach as significance testing,
where null and alternative hypotheses are defined, acceptable type I and II errors are chosen,
and a decision is made at the end of the trial via the p-value regarding the null hypothesis [25,
26]. Royall [7] describes some of the flaws in using this approach for interpreting its results as
evidence. It is beyond the scope of this manuscript to discuss these details, but chief among
them is the requirement to choose between two hypotheses at the end of the trial; i.e., the
choice to reject or fail to reject the null hypothesis. There is no allowance made for “weak”
evidence in favor of one or the other hypothesis or even strong evidence in favor of the null
hypothesis. Royall [7] and Blume [27] argue for likelihood-based approaches in clinical trial
design and regard likelihood-based approaches as the evidential paradigm.

The Neyman-Pearson theory and the evidential paradigm are both based on the likelihood ratio,
but each uses it in a different way. The Neyman-Pearson theory bases inferences on the
probability that the likelihood ratio will be larger than some value, k, if the null hypothesis is true.
The evidential paradigm is based on the value of the likelihood ratio itself and more specifically,
on the law of likelihood:

If hypothesis A implies that the probability of observing some data X is PA(X), and
hypothesis B implies that the probability of observing some data X is PB(X), then the
observation X = x is evidence supporting A over B if PA(x) > PB(x). Further, the likelihood
ratio, PA(x)/PB(x), measures the strength of that evidence [7, 28].

The evidential paradigm uses the likelihood function, evaluated at the observed data, to quantify
evidence regarding a particular hypothesized value of a parameter (see Blume [27] for more
detail on interval construction). The likelihood ratio (LR) is constructed by comparing the
likelihood function, evaluated at different parameter values, based on the observed data.
Suppose we observe 16 responses in 45 patients in a trial (an observed response rate of 0.36)
where our null hypothesis is a response rate of 0.20, and our alternative hypothesis is a
response rate of 0.40. The LR comparing the alternative to the null hypothesis is 15.7 and was
obtained by taking the ratio of the likelihood function at 0.40 to the height at 0.20 (0.83/0.053 =
15.7). A standard frequentist approach would calculate the p-value, which in this case is 0.014,
suggesting strong evidence against the null hypothesized response rate of 0.20.

2.2. A key difference in likelihood versus significance-testing approaches

The significance-testing paradigm and the evidential paradigm have similarities, and often the
inferences reached at the end of a trial would lead to the same conclusions regarding the
success of the trial. However, statistically, there is a critical philosophical difference that should
be considered when deciding which approach is more sensible. In the significance-testing
paradigm, inferences are based on p-values which are calculated ignoring the alternative
hypothesis. The question posed is thus “Is there sufficient evidence to conclude that the null
hypothesis is not true?” The evidential paradigm uses the LR which compares evidence for the
null versus the alternative hypotheses. In essence, the question posed is “Which of these two
hypotheses is more consistent with the observed data?”

Reconsidering our example of an observed response rate of 0.36 in 45 patients, suppose our
null and alternative hypotheses were 0.20 and 0.50, respectively (instead of 0.20 and 0.40). The
observed response rate of 0.36 is almost equally between 0.20 and 0.50, suggesting that the

data do not appear to strongly favor either hypothesis. The p-value remains unchanged at 0.014
because the null hypothesis is the same. The LR is now only 2.80 (LR = 0.15/0.053), implying
rather weak evidence in favor of the alternative hypothesis. The evidential paradigm provides a
result that is consistent with our expectations, but the significance-testing paradigm does not.
This difference in inference is because they ask two different questions.

2.3. Inference in the evidential paradigm

At the end of a study, in the evidential paradigm, a LR is calculated and then interpreted as
evidence. There are three possible types of evidence that are observed: (1) weak evidence, (2)
strong evidence in favor of the correct hypothesis, (3) strong evidence in favor of the incorrect
hypothesis. (This is a bit of a simplification because it presumes that one of the two hypotheses
posed is correct.) Weak evidence arises when there is not sufficiently strong evidence in favor
of either hypothesis. In theory, this can be controlled by increasing the sample size; however, if
neither hypothesis is correct and the true value of the parameter lies somewhere between, then
weak evidence may arise even with a relatively large sample size. Second, strong evidence in
favor of the correct hypothesis can be observed. This is, of course, the goal--to obtain
convincing correct evidence. Lastly, strong evidence in favor of the incorrect hypothesis is
considered misleading evidence (similar to type I and II errors). A trial should terminate early for
futility and rarely terminate when the treatment is effective. The probability of misleading
evidence should be controlled through proper study design and an appropriate choice of K.

The universal bound states that the probability that the LR exceeds k in favor of the wrong
hypothesis can be no larger than 1/k [29, 30]. That is, under the null hypothesis,


L
P 1  k   1
k

 L0

where L1 is the likelihood under the alternative and L0 is the likelihood under the null hypothesis.
An even lower bound applies in some cases (e.g., difference between normal means; large
sample size), but no bound has been shown for the binomial likelihood with relatively small
sample size [31].

Importantly, this bound holds for a sequence of independent observations which allows
repeated estimation of the LR with the bound being maintained [32]. In other words, unlike the
significance-testing paradigm where multiple looks at the data are penalized by increasing type I
error rates, the accumulating data in a clinical trial can be evaluated in a fully sequential fashion,
and the overall rate of misleading evidence will be bounded by 1/K. For a single arm trial with
response as the outcome and K = k, we could estimate the LR after every patient’s response (or
lack of response) had been observed. We would stop the trial if the LR in favor of the null
hypothesis was greater than k, and the probability that we would mistakenly stop the trial early
would be less than 1/k.

Royall proposed guidelines for “strength of evidence” with thresholds of 8 and 32 for classifying
LRs into three levels of evidence [7]. When comparing hypothesis 1 (numerator) to hypothesis 2
(denominator), LRs in the ranges 1-8, 8-32 and >32 would correspond to weak, moderate and
strong evidence regions in favor of hypothesis 1, respectively. However, in exploring the
appropriate values of K in the phase II oncology clinical trial setting, it must be recognized that
weaker evidence is usually acceptable. That is, while phase III comparative trials usually specify
two-sided alpha of 0.05 or one-sided alpha of 0.025, phase II trials very often specify one-sided

alpha of 0.05 or 0.10. As a result, the suggested value of K=8 as a guideline for choosing a
hypothesis may be too high in our application.

2.4. Likelihood-based stopping in single arm phase II studies with binary endpoints

There is strong motivation in oncology research (and other medical research) to terminate single
arm studies as soon as there is convincing evidence that the treatment regimen under study will
not be as effective as desired. The universal bound allows sequential estimation and evaluation
of the LR where early stopping for futility can be enacted when the LR is greater than k in favor
of the null hypothesis. The computational requirement for estimation is trivial: on the log scale,
we would stop the trial at time t, when yt responses had been observed out of Nt patients, if the
following were true:
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 0 
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Note that p0 and p1 are determined prior to the start of the trial so that estimating the likelihood
function at time t simply involves plugging in the number of responses (yt) and the number of
patients (Nt). If LRt is greater than or equal to 1/k, then the trial would continue.

LRt can be calculated after each patient’s response has been observed, and the stopping
criteria can be calculated prior to the start of the trial, simplifying implementation and
computational needs during the trial. Similar to Simon’s two-stage design, we enumerate the
stopping boundaries as part of the trial protocol. Table 1 displays the stopping boundaries
where the null and alternative hypothesized response rates are 0.20 and 0.40, and our

maximum sample size is chosen to be 37 assuming a fully sequential implementation of the trial
where K is chosen to be 8. Each of the thresholds for yt that are listed correspond to the
scenarios under which the likelihood ratio LRt is less than 1/K where K=8.

2.5. The choice of K

Much of the debate in the use of the evidential paradigm has focused on the “correct” choice of
K. In frequentist designs, the clinical trials community is accustomed to alpha of 0.05 or 0.10
and power in the range of 0.80 to 0.90 in phase II trials. As many statisticians will attest, these
choices are somewhat arbitrary, but have become the convention. As a result, we explore
values of K that we would consider appropriate based on previous research but also values of K
that provide similar operating characteristics (acceptance/rejection of hypotheses) to the Simon
designs [7, 8]. In this exploration, we have found that separate values of K for early stopping
and for making a final decision are appropriate to provide similar operating characteristics and
to improve performance in terms of early stopping and decreasing expected sample size under
the null hypothesis. We refer to K for early stopping as interim K, denoted Ki, and K for final
inference (if the study reaches its maximum allowed sample size) is referred to as end K,
denoted Ke.

The probability of misleading evidence is bounded by  ( 2 log(k ) ) regardless of the choice of
sample size [7, 8]. This bound allows us to determine the relationship between values of K and
type I and II errors by equating the probability of misleading evidence to the probability of
rejecting the null when it is true (or, similarly, the probability of failing to reject the null when it is
false). This approach leads to the relationship between alpha and K (Figure 1) which led to the
selection of K=8 for denoting strong evidence (i.e., it corresponds closely to two-sided alpha of

0.05) [7]. However, in our setting, testing is usually one-sided, and the alpha level is often higher
than 0.05. Simon two-stage designs are commonly implemented with an alpha of 0.10 and a
one-sided test, suggesting a lower value of K may be more appropriate in the phase II setting
and, referring to Figure 1, K=2.3 may provide similar operating characteristics to a Simon twostage design with type I and II errors of 0.10. However, there is an asymmetry in the evaluation
of the hypotheses in a futility stopping design: the trial has many opportunities for selecting the
null hypothesis (i.e., failing to reject the alternative), but the alternative hypothesis can only be
selected at the end of the trial. Trials that do not stop early are unlikely to accept the null
hypothesis at the trial’s end and will instead result in weak evidence or strong evidence in favor
of the alternative. Therefore, Ke should be chosen to limit the number of trials that lead to weak
evidence when the alternative hypothesis is true.

3. Results
3.1. Performance of likelihood stopping design compared to Simon’s two-stage
designs

To determine the performance characteristics of the likelihood stopping design (LSD), we
performed simulations of trials and compared the LSD to Simon’s optimal two-stage design
(O2SD) and Simon’s minimax two-stage design (M2SD). In our simulations, the null (H0) is
considered an ineffective level of response, and the alternative (H1) is a response rate that is
sufficiently high to warrant further study of the treatment. The following performance
characteristics were considered:


expected value of the sample size under the null hypothesis



probability of stopping under the null hypothesis



probability of acceptance of H1 under H1 (similar to power)



probability of acceptance of H0 under H0 (similar to 1-alpha).

Although theoretically the properties of a design can be estimated exactly, the computational
burden is significant and increases with the number of possible stopping thresholds. As a result,
simulations were performed (simulating 10,000 trials for each set of conditions) to estimate
performance characteristics.

A scenario is defined by its null (p0) and alternative (p1) response rates. We chose type I and II
errors to be 10% and then identified the optimal and minimax designs for the scenario. We
compared the Simon designs to likelihood designs: one with the maximum sample size of the
optimal design and one with the maximum sample size of the minimax design. We are
consistent with Simon’s notation for his designs: N1 is the stage 1 sample size, N is the total
possible sample size, the trial stops at stage 1 if ≤ r1 responses are seen, we fail to reject the
null if ≤ r responses occur in N patients. We explored different values of K for early stopping
and for final inference and compared the design operating characteristics to the Simon designs
in terms of the probabilities of acceptance and rejection of hypotheses, probability of early
stopping, and expected final sample sizes. Three of our design scenarios are shown here,
although many more were considered.

3.1.1. Scenario 1: p0 = 0.20, p1 = 0.40, Ki =8, Ke =2.3, N=37 (O2SD), N=36 (M2SD)

The O2SD is characterized by N1=17, r1= 3, N=37, and r=9 and the M2SD by N1=22, r1= 4,
N=36, and r=9. LSDs with maximum N of both 37 and 36 were considered to show
comparability to the Simon designs. Table 1 shows the stopping boundaries for the likelihood
designs with Ki=8. Ke=2.3 was chosen to allow comparability to a type I or type II error of 0.10.
Choosing Ki=8 and Ke=2.3, we achieve similar performance under the null as the Simon designs
(Figures 2A and 2B); however, the performance is not directly comparable in the sense that

there are three inferential categories in the likelihood design (strong evidence for H0, strong
evidence for H1, and weak evidence) versus only two categories in the frequentist approach
(reject or fail to reject H0). Figure 2A displays, for the range of true response rates, the
inferential probabilities for each design with a total possible sample size of 37 compared to
O2SD. For a true response rate of 20%, we have strong evidence in favor of the null 91% of the
time, weak evidence 4.4% of the time, and in only 4.3% of trials do we conclude that the
alternative is true (i.e., reject the null). This is almost identical to the O2SD which has a 91%
chance of failing to reject the null and a 9% chance of a type I error. The likelihood design
performs slightly worse under Ki =8 and Ke =2.3 when the alternative is true. For a true
response rate of 40%, the chance of correctly accepting the alternative is 84%, weak evidence
is 5%, and falsely accepting the null is 11%. This is similar to the Simon design which rejects
the null 90% of time and falsely fails to reject only 10% of the time.

When the true response rate is 0.30 (midway between the null and alternative), the LSD has an
88% chance of selecting one of the two hypotheses but 12% of the time will find weak evidence
(LR is between 1/2.3 and 2.3). The O2SD will reject the null 54% of the time and fail to reject
46% of the time. The level of weak evidence for the O2SD may seem low when the true
response rate is 0.30, but there is a relatively low threshold for Ke. Figure 2B shows the
corresponding results for the minimax design, which are quite similar.

Figures 2C and 2D compare expected sample size and probability of early stopping in the
likelihood and Simon designs. Under the null hypothesis, the probability of early stopping with
the likelihood design is 0.82 for both N=37 and N=36, compared with 0.55 and 0.54 for the
Simon optimal and minimax designs, respectively. Under the alternative, the likelihood and
Simon designs have similar early stopping probabilities. One of the most attractive features of
LSDs is the increased chance of early stopping under the null hypothesis which exposes fewer

patients to an ineffective therapy as demonstrated in Figure 2D where the expected sample size
under the null hypothesis is 20 for the likelihood designs and 26 and 28 for the O2SD and
M2SD, respectively. Under the alternative, the expected samples sizes are close: E(N|H1) = 35
in the likelihood design and E(N|H1) = 36 in the Simon designs, both designs continuing to the
maximum sample size in the large majority of trials.

3.1.2. Scenario 2: p0 = 0.20, p1 = 0.40, Ki=8, Ke=1, N=37 (O2SD), N=36 (M2SD).

In the previous scenario, the chance of weak evidence could be lowered, suggesting that for
comparison to the Simon designs, Ke=2.3 may be too high and choosing a lower value for Ke
may improve relative performance.

To address this, scenario 2 implements that same early stopping rule (Ki=8); however, for trials
reaching the final sample size, a likelihood ratio threshold is set to 1 (Ke=1). This is the lowest
reasonable bound in the evidential paradigm and eliminates the weak evidence category.
Comparing the likelihood designs in Figures 2A and 2B to those in 3A and 3B (i.e., Ke=2.3 vs.
Ke=1), we see improved operating characteristics in relation to acceptance of the correct
hypothesis at the null and alternative probabilities. Briefly, compared to the scenario with N=37
and Ke=2.3, choosing Ke=1 leads to the same chance of choosing the null when it is true, but
only a relatively small increase in the chance of choosing the alternative (9% vs. 4%) when the
null is true. Operating characteristics under the alternative are also improved when Ke=1 relative
to the case when Ke=2.3. However, the behavior for other true response rates should be
considered. In the previous scenario, when p=0.30, the probability of weak evidence was 0.12.
With Ke=1, when p=0.30 the probability of selecting the null is 0.48, and the chance of selecting
that alternative is 0.52 which are very similar to scenario 1.

Comparing the design with Ki=8, Ke=1 to the Simon designs (Figures 3A and 3B), Simon’s and
the likelihood designs give us almost identical properties under the null and only a relatively
small difference under the alternative. Despite comparable rejection/acceptance of hypotheses,
the early stopping probabilities and expected sample size (Figures 3C and 3D) vary
substantially when comparing the likelihood to the Simon designs. Given that the Ki is the same
as in Scenario 1, the early stopping probabilities and expected sample sizes are the same in
Scenarios 1 and 2. The results in Figure 3 suggest that we can obtain properties as good as the
Simon designs (in terms of rejecting/accepting/failing to reject the correct hypotheses), yet we
will treat fewer patients when the null hypothesis is true.

3.1.3. Scenario 3: p0 = 0.05, p1 = 0.20, Ki=8, Ke=1, N=37 (O2SD), N=32 (M2SD).

A common situation arises in phase II oncology trials when a new treatment is to be tested in a
patient population for which there is no curative therapy. In this case, we may assume a low null
response rate of 5%, and the alternative usually ranges anywhere from 15% to 35% with a 20%
response rate being a fairly common choice for the alternative. This yields an O2SD with N1=12,
r1= 0, N=37, and r=3 and M2SD with N1=18, r1= 1, N=32, and r=3. The likelihood designs have
few opportunities to stop in a situation with a low expected response rate. When choosing Ki=8,
there are only three early stopping opportunities shown in Table 2: 0 responses in 13 patients, 1
response in 22 patients, and 2 responses in 31 patients. It would be expected that with fewer
opportunities for stopping, the likelihood and Simon designs would be more similar in
performance.

Ke was chosen to be 1 for comparability to the Simon designs. The acceptance/rejection of
hypotheses probabilities are similar in pattern to scenario 1: under the alternative hypothesis,
the likelihood designs have a lower chance of choosing the alternative as compared to the

Simon designs (Figure 4A). However, the performance of the likelihood design under the null is
better in the optimal LSD than the O2SD. Figure 4B demonstrates that the M2SD and the LSD
with N=32 are almost identical. In Figures 4C and 4D, the LSDs perform better under the null in
terms of expected sample sizes and early stopping probabilities, although the improvement in
expected number of patients under the null is not as dramatic as in the previous scenarios given
that there are fewer opportunities for stopping. The chance of early stopping under the null in
the likelihood designs is much greater (84%) than in the O2SD (54%), and an even greater
difference exists when comparing the M2SD (84% for the LSD vs. 40% for M2SD). Under the
null, the likelihood designs have expected sample sizes of 21 and 20 with maximum possible
sample sizes of N=37 and N=32, respectively, while the Simon designs have expected sample
sizes of 23 and 26. When comparing the likelihood design to the optimal design with the same
sample size, the difference in expected sample size under the null is only 2, but when
comparing the likelihood design to the minimax design, the expected difference is 6, which is
substantial given that the maximum sample size is only 32. The probabilities of early stopping
under the alternative in the likelihood designs are 9% and 10% for N=37 and N=32 as compared
to 7% and 2% in the Simon designs. However, the expected sample sizes are almost identical
under the alternative (Figure 4D).

3.1.4. Other situations

There are infinitely many possibilities to consider, but due to space limitations, we have only
shown a few here. Additional scenarios are described in section 4. As it turns out, the larger the
null hypothesized response rate, the greater advantage the likelihood design will have on the
expected sample size and on the probability of early stopping when the true response rate is
less than or equal to the null. This is not surprising given the increased number of opportunities
for early looks at the data.

3.2. Comparison to the predictive probability approach

Comparisons have focused on the Simon design because it is most present in oncology trials.
Lee and Liu’s predictive probability design (PPD) may be a more natural comparison due to its
increased number of looks [12]. Despite being Bayesian, the PPD is similar regarding its
treatment of the alternative hypothesis to Simon designs. It relies on the probability that the
response rate is larger than p0, regardless of the proposed alternative. Specifically, early
stopping is based on the probability that the treatment will be deemed efficacious (i.e. p>p0) by
the end of the study (if the study were to be completed) given the data observed at an interim
look. Lee and Liu chose to estimate the predictive probability beginning with the 10th patient in a
trial and to then monitor continuously, although they also explored other non-sequential designs.

Lee and Liu compared PPDs with type I and II levels less than 0.10 to Simon designs with type I
and II error levels less than 0.10 [12]. We have selected a subset of the designs proposed by
Lee and Liu; specifically, the ones with the same sample sizes as the O2SD and M2SD (Table
3). The PPD shows improvements relative to the Simon designs in regards to probability of early
stopping and smaller expected sample sizes under the null. We have added LSDs with the
same maximum sample sizes and Ki=8 and Ke=1 to the comparisons. Table 3 shows type I
errors of less than 0.10 for all LSDS and type II errors ranging from 0.091 to 0.133. Most of the
type II errors are not less than 0.10, but all are negligibly different. Under the null, the expected
sample size is smaller for all LSDs compared to PPDs and Simon designs. Probability of early
termination (PET0) is smallest under the Simon designs and highest under the PPDs, with the
LSDs having stopping probabilities close to but smaller than the PPDs. These results suggest
that the PPDs stop early more often but stop later in the trials given that their expected sample
sizes tend to be larger. We argue that with the primary goal of sparing patients ineffective

treatments, having a smaller expected sample size under the null is the more important
characteristic.

3.3. Sample size calculations for designing likelihood early stopping designs.

A common approach for study design in a frequentist setting is to graph sample size versus
power for a fixed level of alpha and effect size. A similar approach in the likelihood setting for
single arm studies with a binary response is to plot acceptance probabilities of both null and
alternative hypotheses for fixed values of Ki and Ke and fixed p0 and p1. An additional quantity
that can be included is the probability of early stopping under the null (and/or alternative). In the
previous section, we explored study designs with Ki=8 and with Ke values of 2.3 and 1 with null
and alternative hypothesized response rates of 0.20 and 0.40. In Figure 5, four combinations of
Ki and Ke are considered: (A) Ki=8, Ke=8; (B) Ki=8, Ke=2.3; (C) Ki=8, Ke=1; (D) Ki=4, Ke=2.3. In
each panel, sample size is plotted versus the probability of acceptance of a hypothesis and
early stopping under each hypothesis (i.e., p0 = 0.20; p1 = 0.40). Figure 5A suggests that if
proposing Ki = Ke = 8, the sample size should be 50 to ensure at least an 80% chance of
accepting the alternative when it is true and 90% chance of accepting the null when it is true.
This sample size will also yield a very high probability of early stopping under the null (0.90).
Decreasing the K for the final look to Ke=2.3, a required sample size of 38 will provide >90% and
>85% chance of accepting the null and alternative hypotheses (Figure 5B), respectively, when
they are true and >80% chance of early stopping under the null. If the stringency of futility
stopping is decreased to Ki=4 with a final Ke=2.3 (Figure 5D), even increasing the sample size
to N=80 will not provide a sufficiently high probability of accepting the alternative when it is true
due to the high chance of early stopping with somewhat weak evidence. For large sample sizes
(N>60) in Figure 5D, the probability of accepting the null when it is true is greater than 0.98,
implying an imbalance in the likelihood of strong misleading evidence. These sample size

figures help us choose reasonable values for Ki and Ke that lead to acceptable and appealing
design performance characteristics for a range of sample sizes. As an example, inspection of
Figure 5D clearly demonstrates that regardless of sample size, the choice of Ki=4 and Ke=2.3
has poor operating characteristics.
4. Examples

4.1. Clinical trial in patients with non-small cell lung cancer (NSCLC).

A clinical trial has been proposed (and submitted to the NCI) to test the hypothesis that
treatment of advanced stage and refractory NSCLC patients with a novel agent that is FDAapproved for multiple sclerosis will improve the tumor response rate via activation of ceramidePP2A tumor suppressor signaling by binding/targeting I2PP2A oncoprotein leading to c-Myc
degradation, telomerase inhibition, and consequent tumor suppression. The primary endpoint is
disease-control rate (DCR; i.e., the proportion of patients with complete response, partial
response and stable disease) at 8 weeks. Our null hypothesis is that the DCR is 0.30 and our
alternative is 0.50. A likelihood stopping design has been proposed with a likelihood ratio of 8
favoring the null versus the alternative and, at the end of the study, the hypothesis is chosen
which the likelihood ratio favors (i.e., Ke = 1). With a total possible sample size of 46, the
selected design has a 94% chance of accepting the null when it is true and 87% chance of
accepting the alternative when it is true. These are comparable to alpha of 0.06 and power of
87% in the O2SD. However, the expected sample size under the null is 29 in the O2SD versus
22.7 using the LSD.

4.2. Vitamin D3 supplementation in African American adults

A randomized study has been planned in African American adults to determine (1) if 4,000 IU of
Vitamin D3 daily is safe, and (2) if supplementation is able to improve health-related measures,
such as blood pressure and lipids (e.g., cholesterol levels). One-hundred and fifty patients will
be randomized to the supplementation arm and 75 to the placebo arm. The safety endpoint (i.e.,
toxicity) is defined as the incidence of any grade II, III, or IV toxicity (as defined by CTCAE v 4.0)
within the first 16 weeks of treatment in the supplementation arm. The null hypothesis is that
85% of patients will not experience a toxicity and the alternative is that 95% of patients will not
have a toxicity. (This is analogous to a null toxicity rate of 15% and an alternative toxicity rate of
5%). Using a likelihood early stopping approach with these presumed hypotheses, choosing
Ki=8 and Ke=2.3, the probability of accepting the null when it is true is 0.98; the probability of
accepting the null when the alternative is true is 0.07; and the probability of weak evidence is
<0.01 regardless of whether the null or alternative is true. If the null is true (i.e., toxicity rate of
0.15), the probability of early stopping is 0.98 and the expected sample size in the
supplementation arm is only 38. Under the alternative hypothesis (i.e., toxicity rate of 0.05), the
chance of early stopping is only 7% and the expected sample size is 142. If, for practical
implementation, it is decided to evaluate the data after every tenth patient has reached 16
weeks of follow-up, the expected sample sizes under the null and alternative are 45 and 145,
respectively; and the probabilities of accepting the null when it is true and when the alternative
is true are 0.98 and 0.09, respectively. With the same total sample size, the Simon optimal
design can be performed with a type I error of 3.5%, power of 95% and expected sample size
under the null of 69.

5. Discussion

The evidential paradigm provides a natural framework for early stopping in single arm phase II
studies using the likelihood principle and taking advantage of the universal bound which limits

the probability of misleading evidence. The examples shown in Section 3 illustrate that it is
possible to achieve similar acceptance and rejection of proposed hypotheses while improving
upon the early stopping probabilities under the null hypothesis. Implementation of two different
thresholds for evidence - one threshold for early stopping and another threshold for hypothesis
selection at the trial’s end allow us to control the probability of weak and misleading evidence
while increasing the chance of early stopping under the null. Choices of Ki=8 and Ke=1 or 2.3
appear to be reasonable choices. The combination of Ki=8 and Ke=8 yielded weak evidence
relatively frequently. The combination of Ki=4 and Ke=2.3 caused an imbalance in the likelihood
of acceptance of the null when it is true (high probability) versus the alternative when it is true
(low probability). This is due to the asymmetry in the design (which can stop early only for
futility) and to the low threshold for early stopping resulting in 20% or more of trials stopping
early when the treatment is effective.

Although it was not emphasized in our illustrative examples, Figure 2 shows that when the true
response rate is even lower than the null response rate, the chance of early stopping will be
even higher. This is also true of the Simon designs, but because of the increased number of
looks in the likelihood approach, the expected sample size comparisons between the Simon
designs and the likelihood designs tend to more strongly favor the likelihood designs.

Single arm phase II clinical trials with binary endpoints can be designed allowing for more
frequent looks at the data while preserving operating characteristics (i.e., probability of
accepting the correct hypothesis) and improving others (i.e., probability of stopping early under
the null hypothesis). Fewer patients are exposed to ineffective agents, and resources are
preserved by stopping futile trials earlier. Comparisons to the PPD and Simon designs suggest
that LSDs allow earlier stopping (although not necessarily more frequent stopping) and subject
fewer patients to ineffective therapies with little or no increase in error rates. The methods

proposed have been developed into an R library, allowing users to compare the likelihoodbased design to the Simon designs, and to design future trials using sample size graphics.
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Table 1: Early stopping thresholds for p0 = 0.20, p1 = 0.40 with Ki=8 and a maximum
sample size of N=37. Stopping occurs if 1/LRt < 0.125
Number of
Estimated
1/LRt
Number of
patients (Nt)
response rate
responses (yt)
0
8
0
0.10
1
11
0.09
0.11
2
15
0.13
0.095
3
18
0.17
0.11
4
21
0.19
0.12
5
25
0.20
0.10
6
28
0.21
0.11
7
32
0.22
0.096
8
35
0.23
0.11
Table 2: Stopping thresholds for p0 = 0.05, p1 = 0.20 with Ki=8 and a maximum sample
size of N=37. Stopping occurs if 1/LRt < 0.125
Number of
Number of
Estimated
1/LRt
responses (yt)
patients (Nt)
response rate
0
13
0
0.11
1
22
0.045
0.11
2
31
0.065
0.11

Table 3: Comparison of three designs, based on probability of early termination under the null hypothesis (PET0), expected value of
the sample size under the null (E(N0)), and the final decision rule for accepting the null (or failing to reject the null). If there are r or
fewer responses in N patients, the null will be accepted (or fail to be rejected). For each null and alternative hypothesis pair, the first
row represents the sample size selected based on the Simon Minimax Design with α = β = 0.10. The second row corresponds to the
sample size for the Simon Optimal Design with α = β = 0.10. The PPD and LSD were derived using the same maximum sample size.
Simon Two-Stage Design
Predictive Probability Design Likelihood Stopping Design
α = β = 0.10
α = β = 0.10
Ki = 8, Ke = 1
Max N*
PET0 E(N0)
α
β
PET0 E(N0)
α
β
PET0 E(N0)
α
β
0.10 vs. 0.30
25
0.52 20.4 0.095 0.097 0.79 20.0 0.096 0.095 0.73 15.8 0.091 0.125
35
0.66 19.8 0.098 0.099 0.86 22.0 0.062 0.099 0.87 17.1 0.046 0.114
0.20 vs. 0.40
36
0.46 28.3 0.086 0.098 0.86 27.7 0.088 0.094 0.82 20.4 0.082 0.125
37
0.55 26.0 0.095 0.097 0.85 25.1 0.100 0.084 0.82 20.4 0.089 0.109
0.30 vs. 0.50
39
0.37 35.0 0.094 0.100 0.86 32.5 0.096 0.083 0.79 22.1 0.078 0.129
46
0.67 29.9 0.097 0.095 0.88 33.5 0.081 0.088 0.85 22.9 0.058 0.127
0.40 vs. 0.60
41
0.55 33.8 0.095 0.099 0.87 31.1 0.096 0.098 0.78 24.0 0.090 0.118
46
0.56 30.2 0.095 0.100 0.88 32.1 0.091 0.093 0.81 24.8 0.058 0.133
0.50 vs. 0.70
39
0.50 31.0 0.098 0.099 0.87 29.2 0.100 0.095 0.80 21.4 0.084 0.118
45
0.67 29.0 0.096 0.098 0.88 25.4 0.100 0.091 0.85 22.3 0.054 0.126
0.60 vs. 0.80
35
0.82 28.5 0.097 0.100 0.89 25.5 0.090 0.089 0.82 17.8 0.093 0.113
38
0.47 25.4 0.097 0.096 0.88 21.6 0.099 0.081 0.85 18.4 0.088 0.105
0.70 vs. 0.90
25
0.55 20.0 0.091 0.092 0.89 16.4 0.091 0.098 0.80 13.0 0.083 0.123
28
0.54 17.8 0.099 0.090 0.88 15.7 0.100 0.077 0.84 13.4 0.088 0.091
* Max N refers to the maximum sample size the trial would enroll using the Minimax Design sample size and the Optimal Design
sample size.

Figure Captions:
Figure 1: The relationship between K and the significance level (alpha) for one- and twosided hypothesis testing based on the limiting frequency of observing strong misleading
evidence. Specifically, the probability of strong misleading evidence (i.e., a type I or II
error in the frequentist paradigm) is limited by  (  2 log(k ) ) in the evidential paradigm.
Figure 2: Comparison of operating characteristics of Simon designs and LSDs assuming
H0: p=0.20, H1: p=0.40, Ki=8 and Ke=2.3. (A) Probabilities of accepting or rejecting null
and alternative hypotheses and weak evidence based on true response rates; Simon
optimal design versus LSD (max N=37). (B) Probabilities of accepting or rejecting null
and alternative hypotheses and weak evidence based on true response rates; Simon
mimimax design versus LSD (max N=36). (C) Probability of early stopping versus true
response rates for Simon designs and LSDs. (D) Expected sample size versus true
response rates for Simon designs and LSDs.
Figure 3: Comparison of operating characteristics of Simon designs and LSDs assuming
H0: p=0.20, H1: p=0.40, Ki=8 and Ke=1. (A) Probabilities of accepting or rejecting null and
alternative hypotheses and weak evidence based on true response rates; Simon optimal
design versus LSD (max N=37). (B) Probabilities of accepting or rejecting null and
alternative hypotheses and weak evidence based on true response rates; Simon
mimimax design versus LSD (max N=36). (C) Probability of early stopping versus true
response rates for Simon designs and LSDs. (D) Expected sample size versus true
response rates for Simon designs and LSDs.
Figure 4: Comparison of operating characteristics of Simon designs and LSDs assuming
H0: p=0.05, H1: p=0.20, Ki=8 and Ke=1. (A) Probabilities of accepting or rejecting null and
alternative hypotheses and weak evidence based on true response rates; Simon optimal
design versus LSD (max N=37). (B) Probabilities of accepting or rejecting null and
alternative hypotheses and weak evidence based on true response rates; Simon
mimimax design versus LSD (max N=32). (C) Probability of early stopping versus true
response rates for Simon designs and LSDs. (D) Expected sample size versus true
response rates for Simon designs and LSDs.
Figure 5: Sample size plots for various choices of Ki and Ke assuming H0: p=0.20, H1:
p=0.40 for LSDs. P(Hi| Hi) = probability of accepting Hi when it is true, P(stop| Hi) is the
probability of early stopping under Hi. (A) Ki=8 and Ke=8; (B) Ki=8 and Ke=2.3.; (C) Ki=8
and Ke=1; (D) Ki=4 and Ke=2.3.
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